Verition Fund Management
ACET icon

Verition Fund Management’s Adicet Bio ACET Stock Holding History

Verition Fund Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,002
Closed -$96.8K – 3147
2024
Q2 		$96.8K Buy
+5,002
New +$134K ﹤0.01% 2730
2023
Q2 		– Sell
-2,682
Closed -$247K – 2162
2023
Q1 		$247K Buy
+2,682
New +$337K ﹤0.01% 1643

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Verition Fund Management's ACET Position: Q3 2024 in Review

Verition Fund Management sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 5,002 shares — an estimated $96.8K sold.

Verition Fund Management first reported a position in ACET in Q1 2023 and held it in 2 quarters. The position peaked at $247K in Q1 2023. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

  • Verition Fund Management reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 5,002 Adicet Bio shares in Q3 2024, an estimated $96.8K.
  • Verition Fund Management first reported a position in Adicet Bio in Q1 2023 and held it in 2 quarters.
  • Verition Fund Management's Adicet Bio position peaked at $247K in Q1 2023.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.